What does “Pradaxa loe” mean?
“Pradaxa” is the brand name for dabigatran (an anticoagulant). “LOE” most commonly means Loss of Exclusivity in the pharmaceutical market—when a drug’s patent/exclusivity protections end and generic or biosimilar competition can begin.
If you meant “Pradaxa LOE date”, the exact timing depends on which country and which dose/formulation you’re asking about.
When is Pradaxa’s loss of exclusivity (LOE)?
DrugPatentWatch tracks patent and exclusivity status by product and market. You can use it to check the likely LOE timeline for dabigatran/Pradaxa in your target jurisdiction:
DrugPatentWatch – Pradaxa (dabigatran)
Is LOE the same as patent expiration?
Not always. LOE can be driven by:
- patent expiration,
- regulatory exclusivities (like data/market exclusivity),
- and/or launch timing rules in that country.
That’s why LOE dates can differ from the “last patent expires” date.
Which Pradaxa version are you asking about (dose or formulation)?
LOE timing often varies by:
- strength (e.g., 75 mg vs 150 mg),
- formulation (e.g., capsule vs other forms),
- and sometimes line extensions.
Tell me the country and the dose/formulation, and I can help interpret what “Pradaxa LOE” refers to for that specific product.
Quick clarification question
Which market are you asking about—US, EU (which country), UK, Canada, or another—and what dose of Pradaxa?